AdAlta Past Earnings Performance
Past criteria checks 0/6
AdAlta has been growing earnings at an average annual rate of 3.6%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 0.2% per year.
Key information
3.6%
Earnings growth rate
27.9%
EPS growth rate
| Biotechs Industry Growth | 9.6% |
| Revenue growth rate | 0.2% |
| Return on equity | -208.3% |
| Net Margin | -144.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How AdAlta makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3 | -5 | 4 | 4 |
| 30 Sep 23 | 3 | -5 | 4 | 4 |
| 30 Jun 23 | 3 | -5 | 4 | 4 |
| 31 Mar 23 | 3 | -5 | 4 | 3 |
| 31 Dec 22 | 3 | -5 | 5 | 3 |
| 30 Sep 22 | 3 | -6 | 5 | 4 |
| 30 Jun 22 | 3 | -6 | 4 | 4 |
| 31 Mar 22 | 3 | -5 | 4 | 5 |
| 31 Dec 21 | 4 | -5 | 3 | 5 |
| 30 Sep 21 | 4 | -5 | 3 | 6 |
| 30 Jun 21 | 4 | -6 | 3 | 6 |
| 31 Mar 21 | 4 | -5 | 3 | 6 |
| 31 Dec 20 | 4 | -5 | 2 | 6 |
| 30 Sep 20 | 4 | -5 | 2 | 6 |
| 30 Jun 20 | 4 | -6 | 2 | 7 |
| 31 Mar 20 | 4 | -7 | 2 | 5 |
| 31 Dec 19 | 4 | -8 | 2 | 2 |
| 30 Sep 19 | 4 | -7 | 1 | 1 |
| 30 Jun 19 | 4 | -6 | 1 | 0 |
| 31 Mar 19 | 3 | -5 | 1 | 0 |
| 31 Dec 18 | 2 | -4 | 1 | 0 |
| 30 Sep 18 | 2 | -4 | 1 | 0 |
| 30 Jun 18 | 2 | -4 | 1 | 0 |
| 31 Mar 18 | 2 | -4 | 1 | 0 |
| 31 Dec 17 | 2 | -4 | 1 | 1 |
| 30 Sep 17 | 2 | -3 | 1 | 0 |
| 30 Jun 17 | 2 | -3 | 1 | 0 |
| 31 Mar 17 | 1 | -3 | 1 | 1 |
| 31 Dec 16 | 1 | -3 | 1 | 1 |
| 30 Sep 16 | 1 | -2 | 1 | 1 |
| 30 Jun 16 | 1 | -1 | 0 | 0 |
| 30 Jun 15 | 1 | -1 | 0 | 0 |
| 30 Jun 14 | 1 | -1 | 0 | 0 |
| 30 Jun 13 | 1 | -1 | 0 | 0 |
Quality Earnings: 1AD is currently unprofitable.
Growing Profit Margin: 1AD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1AD is unprofitable, but has reduced losses over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare 1AD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1AD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 1AD has a negative Return on Equity (-208.31%), as it is currently unprofitable.